Activatable cell penetrating peptides with quenched fluorophores
The invention provides compositions useful as molecular probes. In particular, the invention provides activatable cell penetrating peptides comprising a fluorescence donor and a fluorescence acceptor. Exemplary fluorescence donors and fluorescence acceptors include compounds derived from cyanine. Also provided are ratiometric, multispectral, and excitation lifetime imaging methods for detecting the molecular probes provided herein.
1. A compound comprising the structure:
PAP-CL-PCP
wherein:
PAP is a polyanionic peptide comprising:
(i) a series of 5 to 9 glutamate residues, and
(ii) a fluorescence acceptor comprising a cyanine;
CL is a first linker, wherein the first linker is a peptide sequence;
PCP is a polycationic peptide comprising:
(i) a series of 5 to 9 arginine residues, and
(ii) a fluorescence donor comprising a cyanine; and
a targeting moiety attached to the polyanionic peptide via a second linker, wherein the targeting moiety is cyclic(RGD) or cyclic(RGDfK).
2. The compound of claim 1 , wherein the second linker is attached to a derivatized amino acid in the polyanionic peptide.
3. The compound of claim 1 , wherein the second linker comprises poly(ethyleneglycol).
4. The compound of claim 1 , wherein the fluorescence donor is attached to a derivatized amino acid in the polycationic peptide.
5. The compound of claim 1 , wherein the polyanionic peptide comprises five consecutive glutamate residues.
6. The compound of claim 1 , wherein the polycationic peptide comprises eight consecutive arginine residues.
7. The compound of claim 2 , wherein the derivatized amino acid in the polyanionic peptide is cysteine.
8. The compound of claim 4 , wherein the derivatized amino acid in the polycationic peptide is cysteine.
9. The compound of claim 1 , wherein the first linker comprises a peptide having an amino acid sequence selected from the group consisting of (SEQ ID NO: 5) oPLGC Me AG, (SEQ ID NO: 7) PLGC Me AG, (SEQ ID NO: 8) PLGLAG, (SEQ ID NO: 4) RLQLKL, (SEQ ID NO: 2) PPRSFL, and (SEQ ID NO: 1) DPRSFL.
10. The compound of claim 1 , wherein the fluorescence donor is Cy5.
11. The compound of claim 1 , wherein the fluorescence acceptor is Cy7.
12. The compound of claim 1 , wherein the fluorescence acceptor is a non-fluorescent quencher.
13. A method of detecting a tumor, comprising:
(a) contacting a region of interest with the compound of claim 1 ;
(b) illuminating the region of interest on the subject with light having a first wavelength, the first wavelength excites the donor fluorophore but not the acceptor fluorophore; and
(c) detecting fluorescent emissions from the donor and acceptor fluorophore at the region of interest.
14. A method for detecting activity of a proteolytic enzyme in a subject in need thereof,
comprising:
(a) administering to the subject a compound of claim 1 ;
(b) illuminating a region of interest on the subject with light having a first wavelength, the first wavelength excites the donor fluorophore but not the acceptor fluorophore; and
(c) detecting fluorescent emissions from the donor and acceptor fluorophores at the region of interest.
15. A method for detecting a cancerous tissue in a subject in need thereof, comprising:
(a) administering to the subject a compound of claim 1 ;
wherein the first linker is cleavable by MMP2, MMP9, or an elastase;
(b) illuminating a region of interest on the subject with light having a first wavelength, the first wavelength excites the donor fluorophore but not the acceptor fluorophore; and
(c) detecting fluorescent emissions from the donor and acceptor fluorophores.
16. The method of claim 15 , wherein the cancerous tissue is detected in real-time during a surgical procedure.
17. The method of claim 16 , wherein the fluorescent emissions detected in (c) are used to determine the surgical margins for a resection of a tumor or tissue.
18. A method for detecting a blood clot in a subject, comprising:
(a) administering to the subject a compound of claim 1 ;
(b) illuminating a region of interest on the subject with light having a first wavelength, the first wavelength excites the donor fluorophore but not the acceptor fluorophore; and
(c) detecting fluorescent emissions from the donor and acceptor fluorophores.
19. The method of claim 18 , wherein the blood clot is detected in real-time during a surgical procedure.
20. A method for detecting an atherosclerotic plaque in a subject, comprising:
(a) administering to the subject a compound claim 1 ;
(b) illuminating a region of interest on the subject with light having a first wavelength, the first wavelength excites the donor fluorophore but not the acceptor fluorophore; and
(c) detecting fluorescent emissions from the donor and acceptor fluorophores.
21. The method of claim 20 , wherein the atherosclerotic plaque is detected in real-time during a surgical procedure.
22. The method of claim 14 , further comprising:
(d) calculating a ratio of fluorescent emissions at a first wavelength near or at an emission maximum of the donor fluorophore: fluorescent emissions at a second wavelength near or at an emission maximum of the acceptor fluorophore.
23. The method of claim 22 , further comprising displaying an image of the one or more regions of interest on the subject, the image being pseudocolored according to the ratio of fluorescent emissions at a first wavelength near or at an emission maximum of the donor fluorophore: fluorescent emissions at a second wavelength near or at an emission maximum of the acceptor fluorophore.
24. The method of claim 14 , further comprising:
(d) deconvoluting a multispectral image of the region of interest to determine fluorescent emission contributions from the donor and acceptor fluorophores.
25. The method of claim 14 , further comprising:
(d) displaying a multispectral image of the region of interest, the multispectral image comprising information on the fluorescent emissions of the donor and acceptor fluorophores.
26. The method of claim 25 , wherein the multispectral image is pseudocolored according to one or more threshold values.
27. The method of claim 25 , wherein the multispectral image is pseudocolored according to a continuous gradient of component contributions.
28. The method of claim 14 , wherein the first linker comprises a peptide having an amino acid sequence selected from (SEQ ID NO: 5) oPLGC Me AG, (SEQ ID NO:7) PLGC Me AG, (SEQ ID NO: 8) PLGLAG, and (SEQ ID NO:4) RLQLKL.
29. The method of claim 18 , wherein the first linker comprises a peptide having an amino acid sequence selected from (SEQ ID NO:2) PPRSFL and (SEQ ID NO: 1) DPRSFL.